Precio CARsgen Therapeutics Holdings Limited (02171.HK)

CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 371 full-time employees. The company went IPO on 2021-06-18. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The firm conducts its business in the domestic and overseas markets.